Ab Initio Biotherapeutics

Ab Initio Biotherapeutics is an antigen discovery company. Its proprietary antigen discovery platform allows for the targeting of multi-transmembrane proteins, such as GPCRs, and facilitates the generation of antibodies related to various therapeutic indications, including neurological, cardiovascular, endocrine, and gastrointestinal diseases.